Hemostasis Today

March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
Mar 16, 2026, 16:14

Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk

Siobhan Calafiore, Senior Journalist at the limbic, shared a post on  LinkedIn about a recent article she authored, published in The Limbic:

“This week I reported on the landmark COBRRA trial addressing one of the common clinical dilemmas for haematologists treating community-acquired blood clots, ‘which anticoagulant do I give my patient?’

For years, clinical guidelines have been unable to preference one DOAC over the other due to a complete lack of head-to-head trials.

The latest findings suggest while both DOACs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, more than halving the risk of bleeding.

Australia had a big role to play in this practice-changing study and I was lucky enough to chat to Australia’s lead investigator Vivien Chen about the practical difference these findings will make in everyday practice around the world. ”

Title: Landmark VTE trial backs apixaban over rivaroxaban

Authors: Siobhan Calafiore

Read the Full Article on The Limbic

Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk

 

 

 

 

 

 

 

 

 

Stay updated on all scientific advances with Hemostasis Today.